HC Wainwright Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA)

HC Wainwright reaffirmed their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA) in a research note released on Wednesday,Benzinga reports. HC Wainwright currently has a $18.00 price target on the stock.

Several other research analysts have also commented on TNYA. Leerink Partners restated an “outperform” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital reissued a “buy” rating and issued a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Wednesday. Piper Sandler restated an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $16.00 price target on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tenaya Therapeutics has a consensus rating of “Buy” and an average target price of $17.33.

Tenaya Therapeutics Stock Up 18.4 %

TNYA stock opened at $1.67 on Wednesday. The company has a market cap of $132.30 million, a price-to-earnings ratio of -1.16 and a beta of 2.72. The business has a fifty day simple moving average of $2.43 and a 200-day simple moving average of $2.69. Tenaya Therapeutics has a 52 week low of $0.99 and a 52 week high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. As a group, analysts expect that Tenaya Therapeutics will post -1.35 earnings per share for the current fiscal year.

Institutional Trading of Tenaya Therapeutics

Several large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its position in shares of Tenaya Therapeutics by 12.3% during the second quarter. Bank of New York Mellon Corp now owns 237,597 shares of the company’s stock worth $737,000 after purchasing an additional 26,103 shares in the last quarter. Panagora Asset Management Inc. purchased a new stake in Tenaya Therapeutics during the 2nd quarter worth $164,000. Rhumbline Advisers lifted its holdings in Tenaya Therapeutics by 10.5% in the 2nd quarter. Rhumbline Advisers now owns 78,160 shares of the company’s stock worth $242,000 after buying an additional 7,441 shares in the last quarter. American Century Companies Inc. boosted its position in Tenaya Therapeutics by 27.7% in the 2nd quarter. American Century Companies Inc. now owns 102,114 shares of the company’s stock valued at $317,000 after buying an additional 22,146 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Tenaya Therapeutics by 42.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 102,026 shares of the company’s stock valued at $316,000 after buying an additional 30,446 shares during the last quarter. Institutional investors and hedge funds own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.